<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316689</url>
  </required_header>
  <id_info>
    <org_study_id>1801P2011</org_study_id>
    <nct_id>NCT04316689</nct_id>
  </id_info>
  <brief_title>First-in-human Study of S-588210 (S-488210+S-488211)</brief_title>
  <official_title>Open-label, Phase 1 Study of S-488210/S-488211 to Evaluate the Safety and Tolerability in Patients With Unresectable Recurrent and/or Metastatic Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the safety and tolerability of S-588210
      (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Adverse events will be classified by system organ class and preferred term using Medical Dictionary for Regulatory Activities (MedDRA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytotoxic T Lymphocyte (CTL) Induction Rate</measure>
    <time_frame>Baseline and Weeks 8 and 12</time_frame>
    <description>CTL induction is defined as the increase in CTL activity at any point after baseline. Accordingly, the CTL induction rate is calculated as the percentage of participants who show CTL induction to at least any of the 5 antigens.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>S-588210 (S-488210 + S-488211)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous injections once a week for 4 weeks and then a biweekly extension treatment for 8 weeks. Each treatment will consist of 1 subcutaneous injection of 1 mL of S- 488210 and 1 subcutaneous injection of 1 mL of S-488211 containing 1 mg each of the 5 peptides.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S-488210</intervention_name>
    <description>S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).</description>
    <arm_group_label>S-588210 (S-488210 + S-488211)</arm_group_label>
    <other_name>S-588210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S-488211</intervention_name>
    <description>S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).</description>
    <arm_group_label>S-588210 (S-488210 + S-488211)</arm_group_label>
    <other_name>S-588210</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with unresectable recurrent and/or metastatic solid tumor of lung,
             esophageal, head and neck, mesothelioma, or bladder cancer (including urothelial
             cancer of renal pelvis, ureters, and urethra), who have progressed after conventional
             systemic therapies or have exhausted or are intolerant to existing treatment options.

          2. Human leukocyte antigen (HLA)-A*02:01-positive patients.

          3. Patients who are male or female aged ≥18 years at the time of informed consent.

          4. Patients with the Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0
             or 1 at enrollment.

          5. Patients who have a lymphocyte count accounting for 15% or higher of the total white
             blood cell count within 28 days before enrollment.

          6. Patients who provide a personally signed and dated informed consent document for
             participation in the study.

          7. Patients with expected life-span of at least 3 months from the time of enrollment.

        Exclusion Criteria:

          1. Patients who are expected to require any of the following therapies between enrollment
             and completion of the Observation Period.

               -  Anti-malignant tumor drug

               -  Systemic corticosteroid (except for corticosteroid defined as the equivalent of
                  prednisone ≤ 10 mg/day orally)

               -  Systemic immunosuppressant drug

               -  Radiotherapy (except for restricted radiotherapy for pain relief of bone
                  metastasis) for the cancer(s)

               -  Surgical therapy for the cancer(s)

               -  Hyperthermia for the cancer(s)

               -  Traditional Chinese herbal medicine with anti-tumor or immunosuppressant effect

               -  Other investigational products

          2. Patients who have severe concurrent hepatic impairment, renal impairment, heart
             disease, hematological disease, respiratory disease, or metabolic disease, with the
             exception of any symptoms and/or signs associated with cancer(s).

          3. Patients who have known human immunodeficiency virus infection.

          4. Patients with uncontrolled systemic or active infection.

          5. Patients who had any diseases with the risk of sudden death within 12 months before
             enrollment.

          6. Patients with a history or evidence of autoimmune diseases and/or immunodeficiencies.

          7. Female patients who are pregnant, breastfeeding, or have a positive pregnancy test at
             the predose examinations.

          8. Patients who are considered ineligible for this study by the investigator or
             subinvestigator due to any reasons, including inability to understand and follow the
             requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <phone>800-849-9707</phone>
    <email>Shionogiclintrials-admin@shionogi.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>University College London Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic solid tumor</keyword>
  <keyword>Unresectable recurrent solid tumor</keyword>
  <keyword>S-588210</keyword>
  <keyword>Peptide vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

